简体中文
繁體中文
English
Pусский
日本語
ภาษาไทย
Tiếng Việt
Bahasa Indonesia
Español
हिन्दी
Filippiiniläinen
Français
Deutsch
Português
Türkçe
한국어
العربية
Abstract:By David Lawder WASHINGTON (Reuters) – The U.S. Trade Representatives Office said on Thursday it is seeking public comment on whether to restore tariffs on 81 Chinese medical product import categories related to the fight against COVID-19.
USTR seeks public comment on restoring tariffs on Chinese medical products
By David Lawder
WASHINGTON (Reuters) – The U.S. Trade Representatives Office said on Thursday it is seeking public comment on whether to restore tariffs on 81 Chinese medical product import categories related to the fight against COVID-19.
The trade agency said in a statement that it was extending exclusions from tariffs on the 81 products imposed by former president Donald Trump for another 75 days through May 15 to allow for comments from industry and other stakeholders.
The exclusions from 7.5% tariffs on the products, including face masks, examination gloves and hand sanitizing wipes, were due to expire on Feb. 28. The exclusions were first granted in 2020 and had been routinely extended since then as the COVID-19 pandemic wore on.
According to a Federal Register notice, USTR will open a docket for comments from Feb 6 through March 7.
The move to consider restoring the tariffs comes as USTR conducts a four-year review of the Section 301 tariffs and senior U.S. and Chinese officials have pledged to re-engage on economic issues after years of escalating tensions.
(Reporting by David Lawder; editing by Jonathan Oatis and Deepa Babington)
Crude Oil Price Forecast – Crude Oil Markets Looking for BuyersGBP/JPY Forecast – British Pound Plunges Against YenGBP to USD Forecasts: A Return to $1.2350 US Jobs Report DependentEli Lilly Drops 5% As Q4 Revenue Misses EstimatesDespite Relentless Selling Natural Gas Has Corrected Slightly More Than AverageGBP/USD Edges Lower after Bank of England Signals Smaller Future Rate HikesLoadingLoadingLoading
Disclaimer:
The views in this article only represent the author's personal views, and do not constitute investment advice on this platform. This platform does not guarantee the accuracy, completeness and timeliness of the information in the article, and will not be liable for any loss caused by the use of or reliance on the information in the article.